Critical Survey: Bio-Rad Laboratories (NYSE:BIO) versus Prenetics Global (NASDAQ:PRE)

Bio-Rad Laboratories (NYSE:BIO) and Prenetics Global (NASDAQ:PRE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Bio-Rad Laboratories and Prenetics Global”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.67 billion	2.90	-$637.32 million	($27.33)	-10.12
Prenetics Global	$21.74 million	3.05	-$62.72 million	($3.99)	-1.36

Prenetics Global has lower revenue, but higher earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 17.1% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 7.8% of Prenetics Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Bio-Rad Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Prenetics Global has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500.

Profitability

This table compares Bio-Rad Laboratories and Prenetics Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	-30.18%	3.74%	2.65%
Prenetics Global	-191.73%	-16.45%	-13.34%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Bio-Rad Laboratories and Prenetics Global, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0	2	3	0	2.60
Prenetics Global	0	0	1	0	3.00

Bio-Rad Laboratories currently has a consensus price target of $395.20, suggesting a potential upside of 42.90%. Prenetics Global has a consensus price target of $9.00, suggesting a potential upside of 65.59%. Given Prenetics Global’s stronger consensus rating and higher possible upside, analysts clearly believe Prenetics Global is more favorable than Bio-Rad Laboratories.

Summary

Bio-Rad Laboratories beats Prenetics Global on 8 of the 14 factors compared between the two stocks.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.